The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

Research output: Contribution to journalArticlepeer-review

Standard

The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. / Mullish, Benjamin H.; Quraishi, Mohammed Nabil; Segal, Jonathan P.; McCune, Victoria L.; Baxter, Melissa; Marsden, Gemma L; Moore, David; Colville, Alaric; Bhala, Neeraj; Iqbal, Tariq H.; Settle, Christopher; Kontkowski, Graziella; Hart, Ailsa L.; Hawkey, Peter M.; Williams, Horace R. T.; Goldenberg, Simon D.

In: The Journal of hospital infection, Vol. 100, No. Supplement 1, 01.09.2018, p. S1-S31.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Mullish, Benjamin H. ; Quraishi, Mohammed Nabil ; Segal, Jonathan P. ; McCune, Victoria L. ; Baxter, Melissa ; Marsden, Gemma L ; Moore, David ; Colville, Alaric ; Bhala, Neeraj ; Iqbal, Tariq H. ; Settle, Christopher ; Kontkowski, Graziella ; Hart, Ailsa L. ; Hawkey, Peter M. ; Williams, Horace R. T. ; Goldenberg, Simon D. / The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. In: The Journal of hospital infection. 2018 ; Vol. 100, No. Supplement 1. pp. S1-S31.

Bibtex

@article{f4831831af5e44dfbdfd7a68599136fc,
title = "The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications:: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines",
abstract = "Faecal microbiota transplant (FMT) involves the transfer of a sample of faeces from a healthy donor to a recipient. There are several different ways to administer the transplant, including via endoscopy, rectally as an enema, via nasogastric/nasoenteral tube (tube passed through the nose into the stomach/upper part of the small intestine), or via oral ingestion of capsules that contain faecal material. The transplant may either be administered fresh (i.e. immediately after preparation), or may be prepared in advance, stored in a freezer and thawed when required. FMT is an accepted and effective treatment for recurrent infection by Clostridium difficile, a bacterium which can cause severe illness with diarrhoea, most commonly in frail elderly populations as a complication of antibiotic use. Despite adequate treatment, Clostridium difficile infection recurs in about 25% of patients, and some may suffer multiple recurrences.This guideline reviews the evidence for FMT as a treatment for Clostridium difficile infection (CDI) and other conditions. Recommendations are made for: which patients are most likely to benefit, how donors should be selected and screened, how FMT should be prepared and administered, how patients should be followed up, and how FMT services should be configured.",
keywords = "microbiota, faecal transplant, Clostridium difficile, inflammatory bowel disease",
author = "Mullish, {Benjamin H.} and Quraishi, {Mohammed Nabil} and Segal, {Jonathan P.} and McCune, {Victoria L.} and Melissa Baxter and Marsden, {Gemma L} and David Moore and Alaric Colville and Neeraj Bhala and Iqbal, {Tariq H.} and Christopher Settle and Graziella Kontkowski and Hart, {Ailsa L.} and Hawkey, {Peter M.} and Williams, {Horace R. T.} and Goldenberg, {Simon D.}",
year = "2018",
month = sep,
day = "1",
doi = "10.1016/j.jhin.2018.07.037",
language = "English",
volume = "100",
pages = "S1--S31",
journal = "The Journal of hospital infection",
issn = "0195-6701",
publisher = "Elsevier",
number = "Supplement 1",

}

RIS

TY - JOUR

T1 - The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications:

T2 - joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines

AU - Mullish, Benjamin H.

AU - Quraishi, Mohammed Nabil

AU - Segal, Jonathan P.

AU - McCune, Victoria L.

AU - Baxter, Melissa

AU - Marsden, Gemma L

AU - Moore, David

AU - Colville, Alaric

AU - Bhala, Neeraj

AU - Iqbal, Tariq H.

AU - Settle, Christopher

AU - Kontkowski, Graziella

AU - Hart, Ailsa L.

AU - Hawkey, Peter M.

AU - Williams, Horace R. T.

AU - Goldenberg, Simon D.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Faecal microbiota transplant (FMT) involves the transfer of a sample of faeces from a healthy donor to a recipient. There are several different ways to administer the transplant, including via endoscopy, rectally as an enema, via nasogastric/nasoenteral tube (tube passed through the nose into the stomach/upper part of the small intestine), or via oral ingestion of capsules that contain faecal material. The transplant may either be administered fresh (i.e. immediately after preparation), or may be prepared in advance, stored in a freezer and thawed when required. FMT is an accepted and effective treatment for recurrent infection by Clostridium difficile, a bacterium which can cause severe illness with diarrhoea, most commonly in frail elderly populations as a complication of antibiotic use. Despite adequate treatment, Clostridium difficile infection recurs in about 25% of patients, and some may suffer multiple recurrences.This guideline reviews the evidence for FMT as a treatment for Clostridium difficile infection (CDI) and other conditions. Recommendations are made for: which patients are most likely to benefit, how donors should be selected and screened, how FMT should be prepared and administered, how patients should be followed up, and how FMT services should be configured.

AB - Faecal microbiota transplant (FMT) involves the transfer of a sample of faeces from a healthy donor to a recipient. There are several different ways to administer the transplant, including via endoscopy, rectally as an enema, via nasogastric/nasoenteral tube (tube passed through the nose into the stomach/upper part of the small intestine), or via oral ingestion of capsules that contain faecal material. The transplant may either be administered fresh (i.e. immediately after preparation), or may be prepared in advance, stored in a freezer and thawed when required. FMT is an accepted and effective treatment for recurrent infection by Clostridium difficile, a bacterium which can cause severe illness with diarrhoea, most commonly in frail elderly populations as a complication of antibiotic use. Despite adequate treatment, Clostridium difficile infection recurs in about 25% of patients, and some may suffer multiple recurrences.This guideline reviews the evidence for FMT as a treatment for Clostridium difficile infection (CDI) and other conditions. Recommendations are made for: which patients are most likely to benefit, how donors should be selected and screened, how FMT should be prepared and administered, how patients should be followed up, and how FMT services should be configured.

KW - microbiota

KW - faecal transplant

KW - Clostridium difficile

KW - inflammatory bowel disease

U2 - 10.1016/j.jhin.2018.07.037

DO - 10.1016/j.jhin.2018.07.037

M3 - Article

C2 - 30173851

VL - 100

SP - S1-S31

JO - The Journal of hospital infection

JF - The Journal of hospital infection

SN - 0195-6701

IS - Supplement 1

ER -